FOLD (Amicus Therapeutics) Float Percentage Of Total Shares Outstanding : 99.42% (As of Dec. 15, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amicus Therapeutics's float shares is 297.08 Mil. Amicus Therapeutics's total shares outstanding is 298.81 Mil. Amicus Therapeutics's float percentage of total shares outstanding is 99.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amicus Therapeutics's Insider Ownership is 1.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amicus Therapeutics's Institutional Ownership is 97.25%.

Amicus Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Amicus Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	297.08	/	298.81
	=	99.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0HF9:UK AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Executives

Bradley L Campbell	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
John F Crowley	director, officer: Executive Chairman	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark	officer: Chief People Officer	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg	officer: General Counsel & Corp. Secy	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Samantha Prout	officer: Principal Accounting Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jeff Castelli	officer: VP, Program Management	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r.	officer: Chief Financial Officer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab	director	1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi	officer: Chief Financial Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Burke W Whitman	director	13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do	officer: Sr Vice President Discovery	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly	director	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth	officer: Chief Medical Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512